Navigation Links
Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
Date:10/23/2008

that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements, including the statements that Duska's ATPace is expected to enter a pivotal Phase 3 clinical trial, Duska's CDP-1050 is expected to commence a Phase 2 clinical trial, the laboratory research will be translated into a new treatment for ill heart failure patients and that the involvement of Dr. Stamler with Duska will provide us with tremendous strategic advantages. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, the licensed portfolio may not lead to the expected results including that our drugs may not improve the efficiency of heart contractility, the NDA may be rejected the involvement of Dr. Stamler will not lead to expected results and we may never successfully commercialize ATPace or any heart failure compounds. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these fil
'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
2. CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team
3. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
4. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
5. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
6. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
7. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
8. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
9. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
10. Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV
11. Leading Lobbying Firm Celebrates Growth and New Name: Troutman Sanders Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 ... today the signage of a distribution agreement with ... is now distributing Myriant’s bio-succinic acid in the ... and Ireland, targeting customers in the industrial and ... distribution powerhouse, Azelis offers a far-reaching chemical portfolio ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... September 02, 2014 The inventors of ... for chronic tinnitus are seeking support for development costs ... Indiegogo platform ( http://igg.me/at/tinaway ), was launched on September ... therapeutic ‘mHealth’ app and is based on ten years ... team of biomedical and software engineers, Dr. Ian Dixon ...
(Date:8/31/2014)... 01, 2014 Available spectra is ... for research and cultivation of a wide range ... proprietary LEDs with proven patented and pending wide ... light uniformity in critical applications in contrast to ... , “Our customers have a large variety of ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... Pacira Pharmaceuticals, Inc., an,acute care specialty pharmaceutical company, today ... addition of a key senior,executive to the company,s management ... a seasoned biopharmaceutical executive with more than,30 years of ... Pacira as the founder and past Chairman and CEO ...
... WOODCLIFF LAKE, N.J., July 9 Par,Pharmaceutical Companies, Inc. ... shipment of 12.5mg and 25mg meclizine HCl tablets immediately. ... of the AB-rated,generic product., Par marketed meclizine prior ... in February 2008. Par has since qualified a new ...
... 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX:,LOR, ... biopharmaceutical company,specializing in the research and development ... of cancer, today announced progress made in,the ... two,research studies on the Virulizin(R) mode of ...
Cached Biology Technology:Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management 2Par Pharmaceutical to Launch meclizine HCL Tablets 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6
(Date:9/2/2014)... long, spiky legs and their propensity for eating anything, ... nightmares. And now research from North Carolina State University ... homes across the eastern United States. , "The good ... any kind of threat to humans," says Dr. Mary ... lead author of a paper about the research. , ...
(Date:9/2/2014)... are done in by it. New research at Rockefeller ... stress gap in mice with very similar genetic backgrounds ... understand the development of psychiatric disorders such as anxiety ... experiences as it goes through its life. And we ... of genes, and as a result, affect an animal,s ...
(Date:9/1/2014)... diet showed some modest improvement in the last decade ... consumption of unhealthy trans fats, but the gap in ... poor. , , An unhealthy diet is closely linked ... healthy diet is an important part of the strategy ... diet quality is important because it can offer guidance ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... York, N.Y. (November 8, 2012) Autism Speaks, the world,s ... the release of biological and clinical data from 383 new ... to researchers. AGRE is a resource for scientists that is ... two or more children on the autism spectrum. These 383 ...
... least 126,000 sites across the U.S. have contaminated groundwater that ... considered "complex," meaning restoration is unlikely to be achieved in ... says a new report from the National Research Council. ... at these sites ranges from $110 billion to $127 billion, ...
... emerging field tissue regeneration, which harnesses the power and healing ... the world are turning their attention to. One of the ... State University, today announced the opening of SDSU,s new Integrated ... research in San Diego. Speaking at the Frontiers ...
Cached Biology News:Autism Speaks announces the release of new genetic data for researchers 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 3